Hypoglycemic drugs: the glucose-lowering classes, and the medicines that raise blood sugar
Hypoglycemic drugs, also called antihyperglycemic or antidiabetic agents, are the medicines that lower blood sugar. Here they are classified in one table with the classes that can cause hypoglycemia, and a second table lists common drugs that increase blood sugar.
At a glance
- Topic
- Type 2 diabetes medicines
- Topic guide
- Diabetes medications
- Sources
- 7 cited, numbered at the bottom; each [n] mark links to its source
- Updated
Hypoglycemic drugs are medicines that lower blood glucose; the same group is called antihyperglycemic or antidiabetic agents. For type 2 diabetes they include metformin, sulfonylureas, meglitinides, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, GLP-1 receptor agonists, tirzepatide, insulin and pramlintide [1]. Only some of them can push glucose too low. The tables below classify the oral agents, mark which classes cause hypoglycemia, and list the common medicines that do the opposite and raise blood sugar.
This guide sits under diabetes medications, which compares every class on A1C, weight and route.
What are hypoglycemic agents? The terms explained
The three names overlap, and textbooks use them loosely:
- Hypoglycemic agent: the older term, literally a drug that lowers glucose. It is still common in phrases such as oral hypoglycemic drugs.
- Antihyperglycemic agent: a drug that lowers high glucose. Pharmacologists prefer it for metformin, SGLT2 inhibitors and similar drugs because they lower raised glucose without driving it below normal on their own.
- Antidiabetic agent: any medicine used to treat diabetes, injectable or oral. Drug databases file the whole group under this name.
The distinction matters in one place: a drug can be antihyperglycemic without being able to cause hypoglycemia, which is the practical question most people are asking.
Oral hypoglycemic drugs: classification table
Eight oral antidiabetic drug classes, grouped by how they act.
| Class | Examples | Mechanism | Causes hypoglycemia alone? |
|---|---|---|---|
| Biguanide | Metformin | Lowers liver glucose output; improves insulin sensitivity | No |
| Sulfonylureas | Glipizide, glimepiride, glyburide | Stimulate insulin release regardless of glucose level | Yes |
| Meglitinides | Repaglinide, nateglinide | Short-acting stimulation of insulin release at meals | Yes |
| DPP-4 inhibitors | Sitagliptin, linagliptin, saxagliptin, alogliptin | Prolong the body's own GLP-1 and GIP | No |
| SGLT2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin | Increase glucose loss in urine | No |
| Thiazolidinediones | Pioglitazone | Increase insulin sensitivity in muscle, fat and liver | No |
| Alpha-glucosidase inhibitors | Acarbose, miglitol | Slow carbohydrate digestion in the gut | No |
| Oral GLP-1 receptor agonist | Semaglutide tablets (Rybelsus) | Glucose-dependent insulin release; less glucagon; slower stomach emptying | No |
The grouping follows the drug classes the ADA Standards compare in Section 9 [1]. Two minor oral agents, colesevelam and bromocriptine, also carry a type 2 diabetes indication but are rarely used for glucose. Many oral agents come as fixed combinations, for example sitagliptin with metformin. The glucose pills guide covers each tablet, and Jardiance for type 2 diabetes covers empagliflozin.
Which diabetes drugs cause hypoglycemia?
The answer depends on whether the drug raises insulin regardless of glucose.
Insulin and the insulin secretagogues, the sulfonylureas and meglitinides, are the medicines the ADA Standards identify with hypoglycemia risk [2]. They raise insulin whether glucose is high or normal, so a missed meal, extra exercise, alcohol or reduced kidney function can tip glucose too low.
The glucose-dependent classes do not cause hypoglycemia on their own but can add to it. The tirzepatide label warns that combining it with a sulfonylurea or insulin raises the risk, including of severe hypoglycemia, and tells prescribers to consider lower doses of those drugs when it is started [3]. Pramlintide carries a boxed warning for severe hypoglycemia when used with insulin, particularly in type 1 diabetes [4].
That is why a drug that does not cause lows itself can still appear on a hypoglycemia checklist. The metformin vs insulin guide sets the two extremes side by side.
Drugs that increase blood sugar
Several common medicines raise glucose, usually modestly, sometimes enough to cause or unmask diabetes.
| Drug group | Examples | What the evidence reports |
|---|---|---|
| Glucocorticoids (steroids) | Prednisone, dexamethasone, hydrocortisone | Steroid diabetes is more frequent with high doses [5] |
| Thiazide diuretics | Hydrochlorothiazide, chlorthalidone | Glycemic adverse events more frequent than with calcium-channel blockers or ACE inhibitors [5] |
| Certain beta-blockers | Not the whole class; the review found differences between agents | Implicated more than other blood pressure drugs [5] |
| Statins | Atorvastatin, rosuvastatin, simvastatin | About 9% higher risk of new diabetes in trials [6]; FDA label change in 2012 [7] |
| Niacin (nicotinic acid) | Prescription niacin | Can alter glycemic control [5] |
| Second-generation antipsychotics | Olanzapine, clozapine, quetiapine | Hyperglycemia, diabetes and ketoacidosis, mainly through insulin resistance [5] |
| Antidepressants at high doses | Several classes | Associated with higher diabetes risk at high daily doses [5] |
| Fluoroquinolone antibiotics | Levofloxacin, ciprofloxacin | Severe glucose disturbances reported, especially at high doses [5] |
| HIV protease inhibitors | Older protease inhibitors | Alter glucose metabolism [5] |
| Calcineurin inhibitors (transplant) | Tacrolimus, cyclosporine | Mainly reduce insulin secretion [5] |
| Beta-agonists and theophylline | Salbutamol (albuterol) at high doses, theophylline | Hyperglycemia; ketoacidosis reported with beta-adrenergic stimulants [5] |
| Hormones | High-dose estrogen contraceptives, growth hormone, somatostatin analogues | May induce hyperglycemia [5] |
| Anticonvulsants and others | Phenytoin, valproic acid, pentamidine | May induce hyperglycemia; pentamidine by direct effect on pancreatic cells [5] |
| Cancer drugs | PI3K and mTOR inhibitors, immune checkpoint inhibitors | Named in the 2026 ADA Standards, with specific management recommendations [1] |
The mechanisms differ: some drugs reduce insulin secretion, some increase insulin resistance, some raise glucose output, and a few damage pancreatic cells directly [5]. The size of the effect also differs widely, from a large rise with high-dose steroids to a small shift in risk with statins. None of this means a prescribed medicine should be stopped; the review that compiled the list advises clinicians to identify and monitor people on these drugs.
Statins and blood sugar: how large is the risk?
The best-quantified example is statins. A collaborative meta-analysis of 13 trials with 91,140 participants found statin therapy associated with a 9% higher risk of developing diabetes over about four years (odds ratio 1.09), or one extra case for every 255 people treated for four years [6]. The authors judged the risk low both in absolute terms and against the reduction in coronary events [6].
In February 2012 the FDA added increases in blood sugar and A1C to statin labels [7]. The meta-analysis authors concluded that clinical practice in people with moderate or high cardiovascular risk should not change [6], which is why the effect is usually handled by monitoring glucose.
Steroids and cancer medicines in the 2026 guidelines
The 2026 ADA Standards include recommendations on drug-induced high blood sugar in the pharmacology section [1]. During glucocorticoid treatment, glucose-lowering therapy is adjusted to keep individual goals. For hyperglycemia caused by mTOR or PI3K inhibitors, cancer drugs that block insulin signalling, metformin is the first-line choice, with insulin kept for severe hyperglycemia because it may blunt the cancer drug's effect. Immunotherapy-related diabetes can need insulin straight away to prevent ketoacidosis.
These are the drugs where a rise in glucose is expected rather than incidental, and where the treating team plans for it. The type 2 diabetes treatments guide shows how these choices sit within the usual treatment sequence.
More in this topic
This guide is part of Diabetes medications.
- Type 2 diabetes treatments: how treatment is chosen, step by step, in current guidelinesType 2 diabetes treatment starts with nutrition, activity and education, adds medicines chosen by heart, kidney and weight goals, and moves to injections such as GLP-1 drugs and insulin when needed. This is the sequence the 2026 ADA Standards describe.
- Prediabetes medication: what the prevention trials showedNo medicine is approved in the US specifically for prediabetes. Metformin has the longest record, cutting diabetes onset by 31% in the Diabetes Prevention Program, less than lifestyle change did; semaglutide and tirzepatide showed larger effects in people with obesity.
- Metformin vs insulin: how much each lowers A1C, and how they differMetformin lowers A1C by about 1.1 percentage points on its own; insulin can lower it as far as needed but brings low blood sugar and weight gain. Here is what the trials measured for each, and when the 2026 ADA Standards use one, the other, or both.
- Jardiance for type 2 diabetes: how empagliflozin works and what its trials foundJardiance is empagliflozin, a once-daily SGLT2 inhibitor tablet, not insulin. It lowers A1C by roughly 0.7 to 0.9 points against placebo, and its heart and kidney trials earned it approvals for heart failure and chronic kidney disease as well as diabetes.
- New diabetes medications: what has been approved recently, and what is comingThe new type 2 diabetes medications approved in 2026, from the Ozempic pill to two once-weekly insulins, the late-stage drugs behind them, and a plain answer to what is replacing metformin.
- Glucose pills: glucose tablets for lows versus pills that lower blood sugarGlucose tablets raise blood sugar to treat a low; diabetes pills lower it. The two meanings, the ADA's 15-15 rule, grams per tablet, and which diabetes pills make lows more likely.
- Can type 2 diabetes be cured? What remission trials showThere is no cure for type 2 diabetes, but trials show remission: normal HbA1c off all glucose-lowering drugs. What diet, surgery and GLP-1 studies achieved, and how long it lasted.
Questions people ask
Is metformin a hypoglycemic drug?
It is an oral hypoglycemic agent in the broad sense, since it lowers blood glucose, but it is better described as antihyperglycemic: on its own it does not usually cause hypoglycemia.
What is the difference between hypoglycemic and antihyperglycemic drugs?
Hypoglycemic drugs lower glucose and some can push it below normal, as insulin and sulfonylureas can. Antihyperglycemic drugs lower high glucose without, on their own, causing lows. In everyday use the terms are often interchanged.
Can prednisone raise blood sugar?
Yes. Glucocorticoids such as prednisone are among the drugs most often linked to high blood sugar, and steroid diabetes is more frequent at high doses [5].
Do statins cause diabetes?
They slightly raise the risk. Across 13 trials, statins were linked to a 9% higher risk of new diabetes, about one extra case per 255 people treated for four years [6].
Sources
Numbered in the order they are first cited. The bracketed numbers in the text link straight to these.
- 19. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.
pmid-41358900· · peer-reviewed - 26. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
pmid-41358894· · peer-reviewed - 3MOUNJARO (tirzepatide) injection prescribing information
fda-mounjaro-label-2025· · regulatory - 4SYMLIN (pramlintide acetate) injection prescribing information
fda-symlin-label-2019· · regulatory - 5Drug-Induced Hyperglycaemia and Diabetes.
pmid-26370106· · peer-reviewed - 6Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
pmid-20167359· · peer-reviewed - 7Cholesterol-lowering drugs get labeling changes (FDA consumer update)
fda-statin-labeling-2012-02-28· · regulatory
Last reviewed and what changed
- · Written: hypoglycemic, antihyperglycemic and antidiabetic terminology, oral antidiabetic classification table, which classes cause hypoglycemia, drugs that increase blood sugar (table), statin risk size, and the 2026 ADA steroid and cancer-drug recommendations.